摘要
目的分析在支气管扩张患者的药物治疗中应用罗红霉素(长期低剂量)联合盐酸氨溴索治疗的价值。方法遵循药物差异分组方式,将该院2016年3月—2019年12月内接收的94例支气管扩张患者分为对照组(47例,盐酸氨溴索常规治疗)和观察组(47例,联合长期低剂量罗红霉素);观察临床疗效、临床指标改善时间、不良反应发生率以及治疗前后咳痰量、肺功能改善情况。结果观察组临床疗效95.7%,对照组83.0%,差异有统计学意义(χ^2=4.029,P<0.05);观察组呼吸困难、双肺哮鸣音、咳嗽消失各指标用时较低,差异有统计学意义(P<0.05);观察组不良反应发生率8.5%,对照组25.5%,差异有统计学意义(χ^2=4.820,P<0.05);治疗后观察组咳痰量明显较少,肺功能各指标改善幅度较大,差异有统计学意义(P<0.05)。结论对支气管扩张患者实施药物治疗,建议在盐酸氨溴索常规治疗的基础上联合低剂量罗红霉素实施长期治疗,可有效提升临床疗效、缩短临床指标时间、降低不良反应发生率并大幅改善肺功能。
Objective To understand the value of roxithromycin(long-term low-dose)combined with ambroxol hydrochloride in the treatment of patients with bronchiectasis.Methods Following the drug difference grouping method,94 patients with bronchiectasis received in the hospital from March 2016 to December 2019 were divided into the control group(47 cases,conventional ambroxol hydrochloride treatment)and the observation group(47 cases,combined with long-term low-dose roxithromycin);observe the clinical efficacy,clinical index improvement time,incidence of adverse reactions,and improvement of sputum volume and lung function before and after treatment.Results The clinical efficacy of observation group was 95.7%,and that of control group was 83.0%,the difference was statistically significant(χ^2=4.029,P<0.05).In the observation group,dyspnea,wheezing in both lungs,and disappearance of coughing took less time,the difference was statistically significant(P<0.05).The incidence of adverse reactions was 8.5%in the observation group and 25.5%in the control group,the difference was statistically significant(χ^2=4.820,P<0.05).After treatment,the amount of sputum in the observation group was significantly less,and various indexes of lung function improved greatly,the difference was statistically significant(P<0.05).Conclusion For patients with bronchiectasis,it is recommended to implement long-term treatment with low-dose roxithromycin on the basis of conventional ambroxol hydrochloride treatment,which can effectively improve the clinical efficacy,shorten the time of clinical indicators,and reduce the incidence of adverse reactions,greatly improve lung function.
作者
王玉兵
张子洲
WANG Yu-bing;ZHANG Zi-zhou(Department of Respiratory Medicine,Changzhou Seventh People's Hospital,Changzhou,Jiangsu Province,213011 China)
出处
《世界复合医学》
2020年第9期171-173,共3页
World Journal of Complex Medicine
关键词
长期低剂量
罗红霉素
盐酸氨溴索
联合治疗
支气管扩张
Long-term low-dose
Roxithromycin
Ambroxol hydrochloride
Combination therapy
Bronchiectasis
